PSYCHOACTIVE DRUG SCREENING

精神活性药物筛查

• 批准号: 2320816
• 负责人: JOHN W FERKANY
• 金额: $ 60万
• 依托单位: NOVA PHARMACEUTICAL CORPORATION
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-07-01 至 1995-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2320816
• 关键词: PSYCHOACTIVE; DRUG; SCREENING

The NIMH Screening Program was established in order to evaluate natural or synthetic compounds with potential central nervous system (CNS) activity from individual scientists engaged in basic or preclinical research. Centrally active natural product extracts are especially of interest in order to search for novel pharmacologic mechanisms. Screening costs are paid for by the NIMH; there are no charges to investigators. Under this contract, investigators may submit compounds for evaluation in receptor- based assays which may be predictive of psychotherapeutic activity. The main purpose of this contract is to aid in the design of new therapeutic agents, to better predict and understand mechanisms of potential side-effects, and to better understand the mechanisms of therapeutic action of new agents. In order to accomplish these broad aims, the NIMH strongly encourages investigators to follow up compounds which display activity (i.e., inhibition of ligand binding or enzyme activity) with additional testing. Additional tests may include, for example, receptor subtypes, preliminary IC50, functional assays, or in vivo activity and will be determined on a case-by-case basis. The NIMH expects that investigators submitting compounds will: 1) publish results obtained from the screening analyses (publications should acknowledge the service provided by the NIMH program); and, 2) provide the NIMH with a copy of the published manuscript. It is planned that the data generated from this program will be entered into an NIMH structure-activity database. This information will serve as a resource to assist in the design and discovery of novel compounds with potential use in the treatment of mental health disorders.

NIMH筛查计划的建立是为了评估自然或 具有潜在中枢神经系统(CNS)活性的合成化合物 来自从事基础或临床前研究的个别科学家。 中枢活性天然产物提取物尤其令人感兴趣 以寻找新的药理作用机制。筛查成本为 费用由NIMH支付；调查人员不会受到任何指控。在这下面 合同，研究人员可以提交化合物在受体中进行评估- 基于可能预测心理治疗活动的化验。 这份合同的主要目的是帮助设计新的 治疗药物，以更好地预测和了解 潜在的副作用，并更好地了解 新药物的治疗作用。为了实现这些广泛的目标， NIMH强烈鼓励调查人员跟进那些 显示活性(即抑制配体结合或酶活性) 通过额外的测试。其他测试可以包括，例如， 受体亚型、初步IC50、功能分析或体内试验 活动，并将视具体情况而定。NIMH预计 提交化合物的调查人员将：1)公布所获得的结果 从筛查分析(出版物应认可该服务 由NIMH程序提供)；以及，2)向NIMH提供 已出版的手稿。 计划将从该程序生成的数据输入 到NIMH结构-活动数据库中。此信息将用作 帮助设计和发现新化合物的资源 在治疗精神健康障碍方面的潜在用途。